For benefits, see the evidence profile in the EtD framework referenced at the end of the previous section, available online. Resuming anticoagulation following GIB or ICH was associated with reduced risk of all-cause mortality (RR, 0.62 247 fewer to 48 fewer per 1000]; very low certainty) and reduced risk of thromboembolism (RR, 0.45 [95% CI, 0.25-0.83]; ARR, 58 fewer per 1000 [95% CI, 80 fewer to 18 fewer per 1000]; low certainty). Resuming anticoagulation following GIB or ICH possibly reduces the risk for PE (RR, 0.35 [95% CI, 0.11-1.11]; ARR, 17 fewer episodes per 1000 [95% CI, 23 fewer to 3 more per 1000]; very low certainty) and VTE (RR, 0.58 [95% CI, 0.26-1.28]; ARR, 16 fewer episodes per 1000 [95% CI, 23 fewer to 11 more per 27 NOVEMBER 2018 x VOLUME 2, NUMBER 22 ASH 2018 VTE GUIDELINES: ANTICOAGULATION MANAGEMENT 3281 1000]; very low certainty), but the estimates are imprecise, and CIs include no effect. Studies assessing DVT found no difference between those resuming anticoagulation therapy and control groups who did not resume therapy (RR, 0.81 [95% CI, 0.31- 2.16]; very low certainty). Harms and burden. Resuming anticoagulation following GIB or ICH was associated with increased risk of major bleeding (RR, 1.57 [95% CI, 1.12-2.21; ARR, 43 more bleeding events per 1000 [95% CI, 9 more to 92 more per 1000]; very low certainty). Other EtD criteria and considerations. There was very little evidence bearing on the other considerations. Whether the intervention is acceptable to key stakeholders likely varies: patient representatives on the panel were comfortable resuming anti- coagulation therapy following bleeding, but providers were concerned about causing harm. The severity of the bleeding, presence of ongoing bleeding risk factors, and elapsed time since the bleeding episode were also felt to influence the acceptability of the intervention. 